Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
Tord Hompland et al.
CANCERS (2021)
Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer
Taylor C. Peak et al.
MOLECULAR CARCINOGENESIS (2020)
CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential
Isabel R. Schlaepfer et al.
ENDOCRINOLOGY (2020)
Treatment of Advanced Prostate Cancer
Min Yuen Teo et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Cancer statistics for African Americans, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions
Molishree Joshi et al.
CELLS (2019)
Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer
Debbie O'Reilly et al.
STEROIDS (2019)
Biological Evolution of Castration-resistant Prostate Cancer
Alastair Davies et al.
EUROPEAN UROLOGY FOCUS (2019)
CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma
Anke Schuelter et al.
BMC CANCER (2018)
The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations
Roddy S. O'Connor et al.
SCIENTIFIC REPORTS (2018)
Hypoxia-induced exosome secretion promotes survival of African-American and Caucasian prostate cancer cells
Gati K. Panigrahi et al.
SCIENTIFIC REPORTS (2018)
Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation
Cong-Hui Yao et al.
PLOS BIOLOGY (2018)
The role of fatty acid β-oxidation in lymphangiogenesis
Brian W. Wong et al.
NATURE (2017)
Vascular abnormalities and development of hypoxia in microscopic melanoma xenografts
Jon-Vidar Gaustad et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade
Thomas W. Flaig et al.
ONCOTARGET (2017)
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Caroline Wigerup et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer
Q. Qu et al.
CELL DEATH & DISEASE (2016)
Lipid metabolic reprogramming in cancer cells
S. Beloribi-Djefaflia et al.
ONCOGENESIS (2016)
Imaging Mass Spectrometry Revealed the Accumulation Characteristics of the 2-Nitroimidazole-Based Agent Pimonidazole in Hypoxia
Yukiko Masaki et al.
PLOS ONE (2016)
Aberrant Lipid Metabolism Promotes Prostate Cancer: Role in Cell Survival under Hypoxia and Extracellular Vesicles Biogenesis
Gagan Deep et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Hypoxia induces triglycerides accumulation in prostate cancer cells and extracellular vesicles supporting growth and invasiveness following reoxygenation
Isabel R. Schlaepfer et al.
ONCOTARGET (2015)
The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
H. B. Ragnum et al.
BRITISH JOURNAL OF CANCER (2015)
Hypoxic Regulation of Glutamine Metabolism through HIF1 and SIAH2 Supports Lipid Synthesis that Is Necessary for Tumor Growth
Ramon C. Sun et al.
CELL METABOLISM (2014)
Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer
Isabel R. Schlaepfer et al.
MOLECULAR CANCER THERAPEUTICS (2014)
HIF-1-Mediated Suppression of Acyl-CoA Dehydrogenases and Fatty Acid Oxidation Is Critical for Cancer Progression
De Huang et al.
CELL REPORTS (2014)
Fatty Acid Uptake and Lipid Storage Induced by HIF-1α Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation
Karim Bensaad et al.
CELL REPORTS (2014)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
I. M. Pires et al.
BRITISH JOURNAL OF CANCER (2012)
Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer
Michael Milosevic et al.
CLINICAL CANCER RESEARCH (2012)
Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results
Aruna Turaka et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Christian M. Metallo et al.
NATURE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Karen E. Knudsen et al.
CLINICAL CANCER RESEARCH (2009)
Discriminative cytotoxicity assessment based on various cellular damages
Hyunsoo Kim et al.
TOXICOLOGY LETTERS (2009)
Hypoxia-Regulated Angiogenic Inhibitors
Angela Messmer-Blust et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2009)
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study
Roy Vergis et al.
LANCET ONCOLOGY (2008)
Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score
Grant D. Stewart et al.
ONCOLOGY REPORTS (2008)
A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study
Christian J. F. Holubarsch et al.
CLINICAL SCIENCE (2007)
Usefulness of hypoxia inducible factor-1 alpha in evaluating the prostatic adenocarcinoma viability following neoadjuvant hormone therapy
Masanori Yasuda et al.
CANCER DETECTION AND PREVENTION (2007)
An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance
Dawn M. Carnell et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
LYVE-1, the lymphatic system and tumor lymphangiogenesis
DG Jackson et al.
TRENDS IN IMMUNOLOGY (2001)
Share Paper
